SCHEMBL13698456

SCHEMBL13698456

FC(F)(F)c1cccc(N2CCN(C3C4CC5CC(C4)C3C5)CC2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ SIGMAR1 Q99720 2/20 0.49
▸ HTR3E A5X5Y0 1/20 0.49
▸ HTR3B O95264 1/20 0.49
▸ HTR1D P28221 1/20 0.49
▸ HTR2C P28335 1/20 0.49
▸ HTR3A P46098 1/20 0.49
▸ HTR3D Q70Z44 1/20 0.49
▸ HTR3C Q8WXA8 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ THRB P10828 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2020441 0.79 HSD11B1 (0.53) ALDH1A1SMN1; SMN2SIGMAR1HTR3EHTR3B
SCHEMBL11150538 0.77 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2SIGMAR1HTR3EHTR3B
SCHEMBL13698443 0.77 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2SIGMAR1HTR3EHTR3B
SCHEMBL28226906 0.77 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2SIGMAR1HTR3EHTR3B
Hydrochloric Acid SCHEMBL11157830 0.76 MAPT (0.51) ALDH1A1SMN1; SMN2SIGMAR1HTR3EHTR3B
SCHEMBL11442075 0.74 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2SIGMAR1HTR3EHTR3B
Hydrochloric Acid SCHEMBL11458029 0.73 MAPT (0.48) ALDH1A1SMN1; SMN2SIGMAR1HTR3EHTR3B
SCHEMBL26706278 0.71 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2KMT2AMAPTHTR7
SCHEMBL26706279 0.71 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2KMT2AMAPTHTR7
SCHEMBL12706910 0.70 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2SIGMAR1HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors BLANCO MIGUEL GARCIA-GUZMAN 2009-09-24 — — US disclosed
US-7563795-B2 Phenyl-piperazine derivatives as modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-07-21 — — US disclosed
US-7563795-B2 Phenyl-piperazine derivatives as modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-07-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 ALDH1A1 2270/4885SMN1; SMN2 4374/4885SIGMAR1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback